Literature DB >> 22453877

Age-at-onset in Huntington disease.

Michael Orth1, Carsten Schwenke.   

Abstract

BACKGROUND: In Huntington disease, the accurate determination of age-at-onset is critical to identify modifiers and therapies that aim to delay it.
METHODS: Retrospective data from the European Huntington's Disease Network's REGISTRY and PREDICT-HD, a longitudinal study in prodromal huntingtin gene expansion mutation carriers. Data (age, gender, CAG repeat length, parent affected, and Unified Huntington's Disease Rating Scale motor score, total functional capacity) from at least three visits in 423 REGISTRY and 124 PREDICT-HD participants were included. Data based extrapolations of individual age-at-onset using generalized linear mixed models based on individual slopes of motor score or total functional capacity, and predictions using the Langbehn, or Ranen formula, were compared with clinicians' estimates.
RESULTS: Concordance was best for the observed age-at-onset in PREDICT-HD and the calculated onset using the PREDICT-HD UHDRS longitudinal motor scores. This was superior to the REGISTRY data. For total functional capacity, the investigator's estimate was 4 years before the data derived age-at-onset. The concordance of predictions of probability of age-at-onset is better with the observed age-at-onset in the PREDICT-HD data (difference in 25%tile -5 to 10 years) than the REGISTRY data (±20 years).
CONCLUSIONS: Estimating or predicting age-at-onset in Huntington disease may be inaccurate. It can be useful to 1) add in the manifest population motor score regression derived age-at-onset as additional motor onset and 2) add total functional capacity regression derived age-at-onset for the onset of functional impact of Huntington disease when patients are in mid- to late-stage.

Entities:  

Year:  2011        PMID: 22453877      PMCID: PMC3164295          DOI: 10.1371/currents.RRN1258

Source DB:  PubMed          Journal:  PLoS Curr        ISSN: 2157-3999


  12 in total

1.  Challenges assessing clinical endpoints in early Huntington disease.

Authors:  Jane S Paulsen; Chiachi Wang; Kevin Duff; Roger Barker; Martha Nance; Leigh Beglinger; David Moser; Janet K Williams; Sheila Simpson; Douglas Langbehn; Daniel P van Kammen
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

2.  CAG repeat number governs the development rate of pathology in Huntington's disease.

Authors:  J B Penney; J P Vonsattel; M E MacDonald; J F Gusella; R H Myers
Journal:  Ann Neurol       Date:  1997-05       Impact factor: 10.422

3.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

4.  Rate of functional decline in Huntington's disease. Huntington Study Group.

Authors:  K Marder; H Zhao; R H Myers; M Cudkowicz; E Kayson; K Kieburtz; C Orme; J Paulsen; J B Penney; E Siemers; I Shoulson
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

5.  Basal ganglia volume and proximity to onset in presymptomatic Huntington disease.

Authors:  E H Aylward; A M Codori; P E Barta; G D Pearlson; G J Harris; J Brandt
Journal:  Arch Neurol       Date:  1996-12

6.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

Authors:  Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout
Journal:  Lancet Neurol       Date:  2009-07-29       Impact factor: 44.182

7.  Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.

Authors:  Nancy S Wexler; Judith Lorimer; Julie Porter; Fidela Gomez; Carol Moskowitz; Edith Shackell; Karen Marder; Graciela Penchaszadeh; Simone A Roberts; Javier Gayán; Denise Brocklebank; Stacey S Cherny; Lon R Cardon; Jacqueline Gray; Stephen R Dlouhy; Sandra Wiktorski; Marion E Hodes; P Michael Conneally; Jack B Penney; James Gusella; Jang-Ho Cha; Michael Irizarry; Diana Rosas; Steven Hersch; Zane Hollingsworth; Marcy MacDonald; Anne B Young; J Michael Andresen; David E Housman; Margot Mieja De Young; Ernesto Bonilla; Theresa Stillings; Americo Negrette; S Robert Snodgrass; Maria Dolores Martinez-Jaurrieta; Maria A Ramos-Arroyo; Jacqueline Bickham; Juan Sanchez Ramos; Frederick Marshall; Ira Shoulson; Gustavo J Rey; Andrew Feigin; Norman Arnheim; Amarilis Acevedo-Cruz; Leticia Acosta; Jose Alvir; Kenneth Fischbeck; Leslie M Thompson; Angela Young; Leon Dure; Christopher J O'Brien; Jane Paulsen; Adam Brickman; Denise Krch; Shelley Peery; Penelope Hogarth; Donald S Higgins; Bernhard Landwehrmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

8.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

9.  Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease.

Authors:  N G Ranen; O C Stine; M H Abbott; M Sherr; A M Codori; M L Franz; N I Chao; A S Chung; N Pleasant; C Callahan
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

10.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

Authors:  D R Langbehn; R R Brinkman; D Falush; J S Paulsen; M R Hayden
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

View more
  7 in total

1.  Beyond the CAG triplet number: exploring potential predictors of delayed age of onset in Huntington's disease.

Authors:  Sonia Di Tella; Maria RIta Lo Monaco; Martina Petracca; Paola Zinzi; Marcella Solito; Carla Piano; Paolo Calabresi; Maria Caterina Silveri; Anna Rita Bentivoglio
Journal:  J Neurol       Date:  2022-08-01       Impact factor: 6.682

2.  Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene.

Authors:  Leire Valcárcel-Ocete; Gorka Alkorta-Aranburu; Mikel Iriondo; Asier Fullaondo; María García-Barcina; José Manuel Fernández-García; Elena Lezcano-García; José María Losada-Domingo; Javier Ruiz-Ojeda; Amaia Álvarez de Arcaya; José María Pérez-Ramos; Raymund A C Roos; Jørgen E Nielsen; Carsten Saft; Ana M Zubiaga; Ana Aguirre
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

3.  Current Status of Huntington's Disease in Korea: A Nationwide Survey and National Registry Analysis.

Authors:  Hyun Sook Kim; Chul Hyoung Lyoo; Phil Hyu Lee; Sang Jin Kim; Mee Young Park; Hyeo-Il Ma; Jae Hyeok Lee; Sook Kun Song; Jong Sam Baik; Jin Ho Kim; Myung Sik Lee
Journal:  J Mov Disord       Date:  2015-01-13

4.  Chorea-Acanthocytosis and the Huntington Disease Allele in an Irish Family.

Authors:  Olwen C Murphy; Orna O'Toole; Collette K Hand; Aisling M Ryan
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2018-10-26

5.  Bioenergetics in fibroblasts of patients with Huntington disease are associated with age at onset.

Authors:  Sarah L Gardiner; Chiara Milanese; Merel W Boogaard; Ronald A M Buijsen; Marye Hogenboom; Raymund A C Roos; Pier G Mastroberardino; Willeke M C van Roon-Mom; N Ahmad Aziz
Journal:  Neurol Genet       Date:  2018-10-04

6.  Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington's disease.

Authors:  Jian Jing Siew; Hui-Mei Chen; Huan-Yuan Chen; Hung-Lin Chen; Chiung-Mei Chen; Bing-Wen Soong; Yih-Ru Wu; Ching-Pang Chang; Yi-Chen Chan; Chun-Hung Lin; Fu-Tong Liu; Yijuang Chern
Journal:  Nat Commun       Date:  2019-08-02       Impact factor: 14.919

7.  Late-onset Huntington's disease with 40-42 CAG expansion.

Authors:  Elisa Capiluppi; Luca Romano; Paola Rebora; Lorenzo Nanetti; Anna Castaldo; Cinzia Gellera; Caterina Mariotti; Antonella Macerollo; M Giuliana Cislaghi
Journal:  Neurol Sci       Date:  2019-12-09       Impact factor: 3.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.